TB-500 and Thymosin Beta-4: Separating the Two
Half the confusion around TB-500 comes from treating it as a synonym for thymosin beta-4. It is not. Here is the actual relationship, and why it changes what you should expect from a datasheet.

Ask three suppliers what TB-500 is and you may get three different answers. That is not always dishonesty — it is a genuine naming mess that has followed this compound for two decades. Sorting it out takes one paragraph, and it changes how you read every datasheet afterwards.
Fragment, not protein
Thymosin beta-4 is a naturally occurring protein of 43 amino acids, one of the most abundant peptides in mammalian cells and a central regulator of the actin cytoskeleton. TB-500 is a synthetic seven-residue fragment corresponding to the actin-binding domain of that protein — the working end, isolated from the rest.
So the two are related, but they are not interchangeable, and material sold under one name should not be quoted with molecular data belonging to the other. If a certificate lists a molecular weight near 4,900 daltons you are looking at the full protein; the short fragment is far lighter.
The actin story
Actin is the protein that builds the internal scaffolding of a cell and lets it change shape, crawl and divide. Thymosin beta-4 sequesters monomeric actin and regulates how readily it polymerises into filaments. Because cell migration is the first step in essentially every tissue-repair model, that single biochemical role is why the sequence turns up across so many unrelated research fields.
- Cell migration and wound-closure assays in culture.
- Corneal and dermal repair models in animals.
- Cardiac tissue models exploring cell survival after ischaemic injury.
- Inflammation-signalling studies, often alongside the full-length protein.
Why results differ between papers
A fragment and its parent protein do not behave identically. The full protein carries binding regions the fragment lacks, so a result reported for thymosin beta-4 does not automatically transfer to TB-500. When you compare two studies, the first question is always which molecule was actually used.
TB-500 is a research chemical and is listed as a prohibited substance in sport by the World Anti-Doping Agency. It is not an approved medicine, and nothing here is guidance for human use.
Practical handling
Lyophilised TB-500 is stable when kept cold, dry and out of the light. The usual failure mode is not chemistry but process: a vial left on the bench during a long protocol, or a working solution kept past its window because the label was never dated.
- 1Bring the sealed vial to room temperature before opening.
- 2Add bacteriostatic water down the glass wall, never onto the cake.
- 3Swirl gently; if foam forms, you have been too enthusiastic.
- 4Date the vial the moment it is reconstituted and refrigerate it.
What to ask a supplier
Ask which sequence the vial contains, in letters, not just the trade abbreviation. Ask for the chromatogram and the mass spectrum for that batch. A supplier who can answer both without hesitation is telling you something about how the material was made.
Related products
See allFrequently asked questions
Are TB-500 and thymosin beta-4 the same?
No. TB-500 is a short synthetic fragment of the actin-binding region of thymosin beta-4, which is a 43-residue protein.
Does the fragment behave like the full protein?
Not always. The parent protein has binding regions the fragment lacks, so findings do not transfer automatically between the two.
Is it permitted in competitive sport?
No. It appears on the WADA prohibited list. Anyone competing under anti-doping rules should treat it accordingly.
Sources and further reading
About the author
Synedica Research Desk
Scientific content team
The Synedica Research Desk writes and maintains the technical library behind the Synedica Europe catalogue. The team compiles publicly available literature, supplier documentation and analytical data into plain-language explainers for laboratory and research audiences.
- Reviews certificates of analysis supplied with every Synedica batch
- Sources claims from peer-reviewed literature and regulator publications
- Publishes review dates and correction notes on every article
Continue reading
See all
BPC-157: What the Literature Actually Describes
Fifteen amino acids, an unusually stable structure and a very large preclinical literature. Here is what BPC-157 is, and what the published work does and does not show.

How to Store Research Peptides
Dry, cold and dark, opened as few times as possible. Everything else is detail — but the detail is where material is lost.

Peptide Purity and HPLC, Explained
Two vials can both claim 99% purity and contain measurably different amounts of peptide. This explains why.